Investigating how immune cells affect treatment resistance in advanced prostate cancer
Official title: The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate Cancer
Funded at Johns Hopkins University · NIH-10810695 · Data updated 2026-11-12
This study is looking at how certain immune cells in your blood might affect how well Bipolar Androgen Therapy works for men with advanced prostate cancer, with the goal of finding ways to make treatments more effective for those who struggle to respond.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $181,813 |
| NIH project number | 5R21CA273501-02 |
| Project ID | NIH-10810695 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced prostate cancer who are undergoing or have undergone Bipolar Androgen Therapy.
✕Less likely to help
Patients with early-stage prostate cancer or those not receiving Bipolar Androgen Therapy may not benefit from this research.
What this research studies
This research focuses on understanding how myeloid-derived suppressor cells (MDSCs) influence the effectiveness of Bipolar Androgen Therapy (BAT) in patients with advanced prostate cancer. The approach involves analyzing blood samples from patients before and after BAT to observe changes in immune cell populations. By identifying the role of these immune cells, the research aims to improve treatment outcomes for patients who may not respond well to current therapies. The study builds on previous findings that suggest a link between immune responses and treatment efficacy.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for advanced prostate cancer, enhancing patient responses to therapy.
How similar studies have gone: Previous research has shown promising results with similar immune-targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Sanin Pena, David Esteban — Johns Hopkins University
- Study coordinator: Sanin Pena, David Esteban
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.